RxDoctor Payments Data

David Liporace, DO

Internal Medicine · West Palm Beach, FLNPI 1184610818

Payments from drug & device makers

$183,390in general payments, 2019–2025

Across 1,170 payments — averaging $156.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$74K
  • Axsome Therapeutics, Inc.$39K
  • Gilead$18K
  • Teva Pharmaceuticals USA, Inc.$13K
  • Amgen$12K
  • Takeda Pharmaceuticals U.S.A., Inc.$5K
  • plus $22K from 51 others

What the payments were for

  • Consulting fees$24,08813%
  • Speaking & faculty fees$128,89970%
  • Travel & lodging$7,7894%
  • Food & beverage$22,59112%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)271$74,467
Axsome Therapeutics, Inc.40$38,850
Gilead33$17,870
Teva Pharmaceuticals USA, Inc.37$13,499
Amgen(2 entities)62$11,624
Takeda Pharmaceuticals U.S.A., Inc.58$5,333
Pfizer56$4,903
Biogen1$2,196
Johnson & Johnson25$2,108
Nevro Corp.18$1,991
Novo Nordisk64$924
Lilly USA, LLC61$908
AstraZeneca49$846
Sanofi-aventis U.S. LLC37$715
GSK34$483
Merck27$445
Boehringer Ingelheim23$435
Otsuka America Pharmaceutical, Inc.15$422
Kowa Pharmaceuticals America, Inc.25$400
Medtronic4$369
Novartis23$359
Corium, LLC17$355
Biohaven Pharmaceuticals, Inc.13$293
Sunovion Pharmaceuticals Inc.16$284
Amarin Pharma, Inc.14$273
Bayer9$231
Harmony Biosciences LLC5$225
Eisai Inc.12$213
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$208
Biohaven Pharmaceutical Holding Company Ltd.12$202
Supernus Pharmaceuticals, Inc.11$188
Lundbeck LLC10$185
Sanofi5$184
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$152
Collegium Pharmaceutical, Inc.8$126
Exact Sciences5$112
Abbott5$107
Idorsia Pharmaceuticals US Inc5$104
Astellas Pharma US Inc6$103
Alkermes, Inc.4$90
Regeneron Healthcare Solutions, Inc.4$79
Aytu Biopharma, Inc.4$67
Scynexis, Inc.2$66
Ironwood Pharmaceuticals, Inc4$57
IBSA Pharma Inc.3$56
Arbor Pharmaceuticals, Inc.3$51
Shire North American Group Inc2$41
Biodelivery Sciences International, Inc.2$31
Sumitomo Pharma America, Inc.1$22
Azurity Pharmaceuticals, Inc.1$22
Impel Pharmaceuticals Inc.1$20
Antares Pharma, Inc.1$19
Dexcom, Inc.1$18
Neurocrine Biosciences, Inc.1$18
Esperion Therapeutics, Inc.1$17
Almatica Pharma LLC1$14
Currax Pharmaceuticals LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$183,390 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$74,147
Medicare patients
294
Services billed
1,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$123,417
EliquisApixaban104$99,224
OzempicSemaglutide79$89,240
MounjaroTirzepatide67$73,546
Dupixent SyringeDupilumab15$58,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$55,177
JanuviaSitagliptin Phosphate40$48,102
BiktarvyBictegrav/Emtricit/Tenofov Ala12$44,908
Zileuton ErZileuton12$28,283
RexultiBrexpiprazole12$27,986
VraylarCariprazine Hcl18$27,605
TradjentaLinagliptin24$23,614
EntrestoSacubitril/Valsartan31$23,343
TivicayDolutegravir Sodium11$23,342
LinzessLinaclotide22$23,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Combivent Respimat$435$167,655155 claims
PfizerEliquis, Celebrex$4,903$108,095117 claims
Novo NordiskOzempic$924$89,24079 claims
Lilly USA, LLCMounjaro$908$73,54667 claims
GileadBiktarvy, Descovy$17,870$67,68023 claims
AbbVieVraylar, Linzess, Synthroid$74,467$56,50691 claims
MerckJanuvia, Belsomra$445$55,77054 claims
GSKTrelegy Ellipta$483$55,17735 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$846$29,64647 claims
Otsuka America Pharmaceutical, Inc.Rexulti$422$27,98612 claims
NovartisEntresto$359$23,34331 claims
Johnson & JohnsonXarelto$2,108$22,98225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in West Palm Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →